LIfT Biosciences is a biotech bringing to market a first-in-class 'off-the-shelf' innate cell therapy called Neutrophil based Leukocyte Infusion Therapy (N-LIfT). N-LIfT is the world's first neutrophil-based cancer therapeutic product that has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT uses a special type of N1a neutrophil with special cancer killing and immune recruitment capabilities, whilst additionally maintaining minimal damage to healthy cells. 

Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for delivering complete remission in all solid tumours. Our planned Series A in 2021 will fund our manufacture scale-up and phase I/II orphan PoC trial is in some of the most challenging solid tumours e.g. Pancreatic (PDAC), Liver (HCC) and Lung (NSCLC).

March-2023: announces breakthrough preclinical data demonstrating dual mode of action, clinical trials to commence in H1 2024

LIfT BioSciences Board of Directors

• Antonin de Fougerolles - Chairman of the Board
• Jonathan Milner - Investor & Board Advisor
• Marco Gottardis - Non-Executive Director
• Dr Bo Rode Hansen PhD, MBA - Non-Executive Director
• Matt Pierce - Board Director, Downing Ventures

LIfT BioSciences Team

• Alex Blyth, CEO & Founder
• Alfonso Quintas Cardama, Chief Medical Officer
• Oxana Polyakova, Chief Scientific Officer

LIfT BioSciences Advisors

• James Spicer
• Holger Karsunky
• John Campbell
• David Pinato
• Kingston Mills